Beam Therapeutics BEAM Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's change in deferred revenue?
- Beam Therapeutics (BEAM) reported change in deferred revenue of -$6.36M in Q1 2026.
- How has Beam Therapeutics's change in deferred revenue changed year-over-year?
- Beam Therapeutics's change in deferred revenue increased by 14.9% year-over-year, from -$7.47M to -$6.36M.
- What is the long-term trend for Beam Therapeutics's change in deferred revenue?
- Over 3 years (2021 to 2025), Beam Therapeutics's change in deferred revenue has grown at a -27.1% compound annual growth rate (CAGR), from $348.92M to -$135.42M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.